# Objective Response Rate of Ivonescimab With Chemotherapy in Locally Advanced Resectable Oral and Oropharyngeal Squamous Cell Carcinoma

> **NCT07686575** · — · RECRUITING · sponsor: **Zhujiang Hospital** · enrollment: 20 (estimated)

## Conditions studied

- HNSCC
- OSCC
- OPSCC
- Ivonescimab

## Interventions

- **DRUG:** Ivonescimab（AK112，a PD-1/VEGF bispecific antibody）

## Key facts

- **NCT ID:** NCT07686575
- **Lead sponsor:** Zhujiang Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-26
- **Primary completion:** 2026-08-30
- **Final completion:** 2028-08-30
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-07-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07686575

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07686575, "Objective Response Rate of Ivonescimab With Chemotherapy in Locally Advanced Resectable Oral and Oropharyngeal Squamous Cell Carcinoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07686575. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*